Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brivekimig dose-ranging study in adults with moderate to severe ulcerative colitis
2024-515241-41-00Phase 2Authorised
- Sponsor
- Sanofi
- Start
- Sep 2025
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 12
01
Overview
Phase 2, randomised, double-blind trial in autoimmune colitis comparing brivekimig dose arm(s) with placebo (2 arms). Primary endpoint: Clinical remission at Week 16 by modified Mayo score. Planned start Sep 2025; status: authorised.
02
Drugs
brivekimig
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2024-515241-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515241-41-00.